Nature Medicine · 1 July 2026 · From issue 04
Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial
A double-acting HIV antibody was safe and well tolerated in its first human trial.
Deborah A. Theodore, Bryan T. Mayer et al.
A new lab-made antibody for HIV showed no serious safety problems in its first human trial. This antibody attaches to two different targets at once. One part sticks to the virus. The other part sticks to a protein on human immune cells. Doctors tested it in 54 people, some with HIV and some without, using shots or IV drips at different doses. The most common side effects were soreness where the shot went in, tiredness, and headache. Three out of nine people with HIV got a body rash about 8 to 12 days after treatment. The rash went away within 9 to 16 days.
Integrity screen: passed (3 checks) Checked 11 August 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue